IDEAYA Biosciences Inc.’s recent filing unveils that its Chief Financial Officer Stone Paul A. unloaded Company’s shares for reported $0.14 million on Aug 29. In the deal valued at $28.87 per share,5,000 shares were sold. As a result of this transaction, Stone Paul A. now holds 9,303 shares worth roughly $ 0.27 million.
Then, Stone Paul A. sold 978 shares, generating $25,819 in total proceeds. Upon selling the shares at $26.40, the Chief Financial Officer now owns 14,303 shares.
Before that, Stone Paul A. sold 3,822 shares. IDEAYA Biosciences Inc. shares valued at $100,820 were divested by the Chief Financial Officer at a price of $26.38 per share. As a result of the transaction, Stone Paul A. now holds 15,281 shares, worth roughly $0.44 million.
SVB Securities initiated its IDEAYA Biosciences Inc. [IDYA] rating to an Outperform in a research note published on Tuesday, August 08, 2023; the price target was $33. PT values the company’s stock at a premium of 12.7 to its Tuesday closing price.
Price Performance Review of IDYA
On Tuesday, IDEAYA Biosciences Inc. [NASDAQ:IDYA] saw its stock fall -3.22% to $28.81. On the same session, the stock had its day’s lowest price of $28.77, but rose to a high of $30.25. Over the last five days, the stock has gained 1.77%. IDEAYA Biosciences Inc. shares have risen nearly 58.56% since the year began. Nevertheless, the stocks have risen 193.98% over the past one year. While a 52-week high of $30.12 was reached on 09/05/23, a 52-week low of $9.00 was recorded on 04/12/23. SMA at 50 days reached $24.18, while 200 days put it at $19.68. A total of 0.63 million shares were traded, compared to the trading of 0.49 million shares in the previous session.
Levels Of Support And Resistance For IDYA Stock
The 24-hour chart illustrates a support level at 28.30, which if violated will result in even more drops to 27.80. On the upside, there is a resistance level at 29.78. A further resistance level may holdings at 30.76. The Relative Strength Index (RSI) on the 14-day chart is 68.93, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.49, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 24.83%. Stochastics %K at 87.75% indicates the stock is a selling.
How much short interest is there in IDEAYA Biosciences Inc.?
A steep rise in short interest was recorded in IDEAYA Biosciences Inc. stocks on Aug 14, 2023, growing by 0.41 million shares to a total of 6.52 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 6.11 million shares. There was a rise of 6.29%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 11.47% of the overall stock float, the days-to-cover ratio (short ratio) rose to 14.2.
IDEAYA Biosciences Inc. [IDYA] – Who Are The Largest Shareholders?
In filings from BVF Partners LP, it is revealed that the company now owns 5,683,489 shares, or roughly 9.87% of the outstanding IDYA shares. In other words, the investor’s shares have risen by 3,228,400 from its previous 13-F filing of 2455089.0. Additionally, BlackRock Fund Advisors increased 21.32% of its stake after which the total value it holdings stand at $85,340,987, while Federated Global Investment Manag added 18.33% of its stake to hold $75.79 million in the firm. Over the last quarter, Avidity Partners Management LP sold -687,700 shares of IDEAYA Biosciences Inc., while The Vanguard Group, Inc. sold 448,929 shares. At present, Adage Capital Management LP is holding 2,575,110 shares valued at $57.58 million. T. Rowe Price Associates, Inc. owned 2,473,878 shares of the company at the time of its most recent 13F filing, worth $55.32 million.